Repositioning Candidate Details
| Candidate ID: | R0912 |
| Source ID: | DB05992 |
| Source Type: | investigational |
| Compound Type: | small molecule |
| Compound Name: | Plinabulin |
| Synonyms: | Plinabulin |
| Molecular Formula: | C19H20N4O2 |
| SMILES: | CC(C)(C)C1=C(\C=C2/NC(=O)\C(NC2=O)=C\C2=CC=CC=C2)N=CN1 |
| Structure: |
|
| DrugBank Description: | -- |
| CAS Number: | 714272-27-2 |
| Molecular Weight: | 336.395 |
| DrugBank Indication: | Investigated for use/treatment in cancer/tumors (unspecified). |
| DrugBank Pharmacology: | -- |
| DrugBank MoA: | NPI-2358 is a vascular disrupting agent currently in clinical development for the treatment of cancer by Nereus. NPI-2358 is one of over 200 synthetic analogues that were prepared following the discovery of the compound Halimide isolated from a marine fungus. In preclinical models of cancer, including lung, breast, sarcoma, colon and prostate, NPI-2358 demonstrated potent and selective anti-tumor effects in combination with docetaxel and other oncology therapies, as well as single-agent efficacy in a number of orthotopic models. NPI-2358 interacts with soluble beta-tubulin and prevents the polymerization of tubulin without altering dynamic microtubule function of formed microtubules. As demonstrated in preclinical testing, this target profile results in a highly specific nanomolar cytotoxicity while reducing the side effects seen in first-generation VDAs due to cardiotoxicity, hemodynamic changes and neuropathies. |
| Targets: | Tumor necrosis factor |
| Inclusion Criteria: | Target associated |
